{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:46:44Z","timestamp":1787647604761,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japan Society of Clinical Oncology","award":["Clinical Research Program Grant"],"award-info":[{"award-number":["Clinical Research Program Grant"]}]},{"name":"Janssen Pharmaceutical K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10147-019-01471-5","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T06:02:50Z","timestamp":1558677770000},"page":"1284-1291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003\/intergroup study)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-9937","authenticated-orcid":false,"given":"Hiroyuki","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eizo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Kigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"1471_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER Cancer statistics review, 1975\u20132014, National Cancer Institute. Bethesda, MD, \n                    https:\/\/seer.cancer.gov\/csr\/1975_2014\/\n                    \n                  . Based on November 2016 SEER data submission, posted to the SEER web site, April 2017"},{"key":"1471_CR2","unstructured":"Center for cancer control and information services, National Cancer center, Japan \n                    https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html\n                    \n                  . Accessed 22 May 2019"},{"key":"1471_CR3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384:1376\u20131388","journal-title":"Lancet"},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bpobgyn.2016.12.001","volume":"41","author":"T Grunewald","year":"2017","unstructured":"Grunewald T, Ledermann JA (2017) Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41:139\u2013152","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1471_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR et al (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139:10\u201316","journal-title":"Gynecol Oncol"},{"key":"1471_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852\u2013861","journal-title":"Lancet Oncol"},{"key":"1471_CR7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/intimm\/dxw020","volume":"28","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi J, Mandai M, Konishi I (2016) Immune checkpoint inhibition in ovarian cancer. Int Immunol 28:339\u2013348","journal-title":"Int Immunol"},{"issue":"Suppl 1","key":"1471_CR8","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","volume":"27","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Minion LE, Coleman RL (2016) Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27(Suppl 1):i33\u2013i39","journal-title":"Ann Oncol"},{"key":"1471_CR9","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.03.28","author":"G Tran","year":"2018","unstructured":"Tran G, Zafar SY (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. \n                    https:\/\/doi.org\/10.21037\/atm.2018.03.28","journal-title":"Ann Transl Med"},{"key":"1471_CR10","unstructured":"Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer. \n                    https:\/\/jsgo.or.jp\/guideline\/ransou2015.html\n                    \n                  . Accessed 22 May 2019"},{"key":"1471_CR11","unstructured":"Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. NCCN clinical practice guidelines in oncology. Version 2.2018-March 9, 2018. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf\n                    \n                  . Accessed 22 May 2019"},{"key":"1471_CR12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361:2099\u20132106","journal-title":"Lancet"},{"key":"1471_CR13","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"1471_CR14","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699\u20134707","journal-title":"J Clin Oncol"},{"key":"1471_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1634\/theoncologist.2009-0331","volume":"15","author":"RW Holloway","year":"2010","unstructured":"Holloway RW, Grendys EC, Lefebvre P et al (2010) Tolerability, efficacy, and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine-carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review. Oncologist 15:1073\u20131082","journal-title":"Oncologist"},{"key":"1471_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/JTO.0b013e3181e2eadf","volume":"5","author":"SJ Mandrekar","year":"2010","unstructured":"Mandrekar SJ, Sargent DJ (2010) Randomized phase II trials: time for a new era in clinical trial design. J Thorac Oncol 5:932\u2013934","journal-title":"J Thorac Oncol"},{"key":"1471_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1046\/j.0306-5251.2001.01381.x","volume":"51","author":"N Stallard","year":"2001","unstructured":"Stallard N, Whitehead J, Todd S et al (2001) Stopping rules for phase II studies. Br J Clin Pharmacol 51:523\u2013529","journal-title":"Br J Clin Pharmacol"},{"key":"1471_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/annonc\/mdi147","volume":"16","author":"AJ Gonz\u00e1lez-Mart\u00edn","year":"2005","unstructured":"Gonz\u00e1lez-Mart\u00edn AJ, Calvo E, Bover I, Rubio MJ, et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16:749\u2013755","journal-title":"Ann Oncol"},{"key":"1471_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/annonc\/mdl376","volume":"18","author":"JM Ferrero","year":"2007","unstructured":"Ferrero JM, Weber B, Geay JF et al (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18:263\u2013268","journal-title":"Ann Oncol"},{"key":"1471_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"DS Alberts","year":"2008","unstructured":"Alberts DS, Liu PY, Wilczynski SP et al (2008) Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 108:90\u201394.","journal-title":"Gynecol Oncol"},{"key":"1471_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ygyno.2007.08.008","volume":"107","author":"A du Bois","year":"2007","unstructured":"du Bois A, Pfisterer J, Burchardi N et al (2007) Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the arbeitsgemeinschaft gyn\u00e4ekologische onkologie studiengruppe ovarialkarzinom (AGO\u2013OVAR) and kommission uterus (AGO-K-Ut) Gynecol Oncol 107:518\u2013525.","journal-title":"Gynecol Oncol"},{"key":"1471_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ygyno.2009.04.037","volume":"114","author":"P Power","year":"2009","unstructured":"Power P, Stuart G, Oza A et al (2009) Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 114:410\u2013414","journal-title":"Gynecol Oncol"},{"key":"1471_CR23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/IGC.0b013e3181a8b938","volume":"19","author":"BL Rapoport","year":"2009","unstructured":"Rapoport BL, Vorobiof DA, Slabber C et al (2009) Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 19:1137\u20131141","journal-title":"Int J Gynecol Cancer"},{"key":"1471_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","volume":"92","author":"CA Papadimitriou","year":"2004","unstructured":"Papadimitriou CA, Fountzilas G, Aravantinos G et al (2004) Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A hellenic cooperative oncology group study. Gynecol Oncol 92:152\u2013159","journal-title":"Gynecol Oncol"},{"key":"1471_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2004.10.011","volume":"96","author":"MF Kose","year":"2005","unstructured":"Kose MF, Sufliarsky J, Beslija S et al (2005) A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol Oncol 96:374\u2013380","journal-title":"Gynecol Oncol"},{"key":"1471_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4149\/neo_2009_04_291","volume":"56","author":"J Sufliarsky","year":"2009","unstructured":"Sufliarsky J, Chovanec J, Svetlovska D et al (2009) Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer. Neoplasma 56:291\u2013297","journal-title":"Neoplasma"},{"key":"1471_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1023\/A:1011605008922","volume":"12","author":"A du Bois","year":"2001","unstructured":"du Bois A, L\u00fcck HJ, Pfisterer J et al (2001) Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer\u2014a dose-finding study by the Arbeitsgemeinschaft gyn\u00e4kologische onkologie (AGO) ovarian cancer study group. Ann Oncol 12:1115\u20131120","journal-title":"Ann Oncol"},{"key":"1471_CR28","doi-asserted-by":"publisher","first-page":"viii332","DOI":"10.1093\/annonc\/mdy285.142","volume":"29","author":"J Pfisterer","year":"2018","unstructured":"J. Pfisterer, A.P. Dean, K. Baumann et al (2018) Carboplatin\/pegylated liposomal Doxorubicin\/Bevacizumab (CD-BEV) vs. Carboplatin\/Gemcitabine\/Bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. Annals of Oncology 29 (suppl_8): viii332\u2013viii358. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdy285\n                    \n                  .","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01471-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01471-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01471-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:47:03Z","timestamp":1590191223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01471-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01471-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"5 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Jichi Medical University, Kurume University School of Medicine, Saitama Medical University International Medical Center, Tottori University School of Medicine, National Defense Medical College Hospital, Osaka University Graduate School of Medicine, Kyushu University, Shizuoka Cancer Center Hospital, Yamagata University School of Medicine, Kansai Rosai Hospital, Iwate Medical University, Kosei Hospital, The Jikei University School of Medicine, Kashiwa Hospital, Hirosaki University School of Medicine & Hospital, Nara Medical University Hospital, Niigata University Medical and Dental Hospital, Mie University Hospital, Ehime University Hospital, Hyogo Medical College Hospital, Miyoshi Central Hospital, Nagaoka Red Cross Hospital, NHO Shikoku Cancer Center, Niigata Cancer Center Hospital, Tottori Municipal Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical institutions"}}]}}